The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
Frontiers in oncology
View this publicationFrontiers in oncology
View this publicationOrphanet journal of rare diseases
View this publicationPublication categories: Top publication
Nature communications
View this publicationAllergy
View this publicationBMC cardiovascular disorders
View this publicationBone research
View this publicationScientific reports
View this publicationCell research
View this publicationDevelopmental cell
View this publicationInnere Medizin (Heidelberg, Germany)
View this publication